The Netherlands Pharmacovigilance Centre Lareb identifies risks associated with the use of medicines in daily practice and is the Knowledge Centre for adverse drugs reactions (ADRs).
Lareb collects 20.000 to 25.000 reports of adverse drug reactions yearly. Analysis of reports lead to signals about adverse drug reactions. These signals are reported to and reviewed by the Dutch Medicines Evaluation Board (MEB). This intensive cooperation supports the MEB in its decisions with regard to its role in pharmacovigilance in the Netherlands and Europe.
The Teratology Information Service (TIS) of Lareb is the Knowledge Centre on safety of drugs used during pregnancy and lactation.
Lareb is an independent foundation and is funded by the MEB and the Ministry of Health.
In May 2013 the Netherlands Pharmacovigilance Centre Lareb was appointed WHO Collaborating Centre for Pharmacovigilance in Education and Patient Reporting.
Please have a look at our annual report in numbers: Highlights 2016